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Summary
Antimicrobials are widely used in preventive and curative medicine in animals.
Benefits from curative use are clear – it allows sick animals to be healthy with a
gain in human welfare. The case for preventive use of antimicrobials is less clear
cut with debates on the value of antimicrobials as growth promoters in the inten-
sive livestock industries. The possible benefits from the use of antimicrobials need
to be balanced against their cost and the increased risk of emergence of resistance
due to their use in animals. The study examines the importance of animals in
society and how the role and management of animals is changing including the
use of antimicrobials. It proposes an economic framework to assess the trade-offs
of anti-microbial use and examines the current level of data collection and analy-
sis of these trade-offs. An exploratory review identifies a number of weaknesses.
Rarely are we consistent in the frameworks applied to the economic assessment
anti-microbial use in animals, which may well be due to gaps in data or the preju-
dices of the analysts. There is a need for more careful data collection that would
allow information on (i) which species and production systems antimicrobials
are used in, (ii) what active substance of antimicrobials and the application
method and (iii) what dosage rates. The species need to include companion ani-
mals as well as the farmed animals as it is still not known how important direct
versus indirect spread of resistance to humans is. In addition, research is needed
on pricing antimicrobials used in animals to ensure that prices reflect production
and marketing costs, the fixed costs of anti-microbial development and the exter-
nalities of resistance emergence. Overall, much work is needed to provide greater
guidance to policy, and such work should be informed by rigorous data collection
and analysis systems.
Introduction
The use of antimicrobials in livestock production provides a
basis for improving animal health and productivity. This in
turn contributes to food security, food safety, animal
welfare, protection of livelihoods and animal resources.
However, there is increasing concern about levels of anti-
microbial resistance in bacteria isolated from human,
animal, food and environmental samples and how this
relates to use of antimicrobials in livestock production. A
common reaction is to assume that antimicrobials should
not be used in livestock. This study will explore why there is
a need for a balance between the contributions of the anti-
microbial use to food security and safety with the costs of
the increased risks of anti-microbial resistance emergence.
Such trade-offs are not simple as there are different types of
antimicrobials different uses of these drugs in livestock and
food systems and a variability of management of animals.
The study looks first at the importance of animals in
societies across the world, the changing management of
these animals and the use of antimicrobials in the produc-
tion systems – the context. It will then examine the
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economic frameworks available to assess the use of anti-
microbials and how these could be applied – the theory.
The following section provides an exploratory review of the
data on the use of antimicrobials and the benefits and costs
– the current evidence. Finally, there are some reflections
on the gaps and why these gaps exist. The discussion
focuses on the need for state interventions that balance the
private short-term benefits against the medium- to long-
term needs of society.
The context – animals in society
Animals are a fundamental aspect of societies around the
world, and they feed people, provide pleasure and com-
pany, act as a store of wealth and, in many places, provide
power to till land and to transport goods and people. In
general, ‘human lives are enhanced by the use of animals’
(Norwood and Lusk, 2011). The sheer number of animals
that humans have domesticated, with 7 billion people hav-
ing 2.65 billion livestock units, underscores this impor-
tance.1 A majority of these domesticated animals are cattle,
sheep, goats, pigs and poultry – livestock that are kept for
food production, transport and draught power and as a
form of investment (see Fig. 1)2 .
Across the world, there are approximately 0.38 livestock
units, or an estimated 190 kilos of live animals per person.
In species terms, this translates to three chickens, a third of
a sheep or goat, a fifth of a cow, a seventh of a pig and a
tenth of a cat or dog per person. The sheer scale of this bio-
mass and the fact that these animals both compete for
resources and share pathogenic and non-pathogenic organ-
isms with humans demand attention to their role in rela-
tion to human health.
The role of animals in society is also changing and will
continue to change in the future. Global human population
is predicted to increase from 7 billion people in 2013 to 9.6
billion in 2050, and this population will be increasingly
urbanised (Gerland et al., 2014). In general, urban popula-
tions are richer than rural ones, and richer populations
demand greater amounts of meat relative to other food
products. This creates demands on global food systems and
more specifically livestock food systems. The response to the
greater demand for livestock products has been a general
increase in the global livestock populations. In addition,
there is an intensification of livestock production systems
with a reliance on diets of concentrated feeds, indoor hous-
ing and use of specialist breeds. These livestock populations
are kept in higher densities clustered in areas with access to
transport and processing systems. The animals are also sed-
entary rarely being allowed to scavenge or graze for food,
rather food is brought to them. The final major change is
that the livestock production systems are part of increasingly
complex and lengthy livestock food systems with inputs
such as grains coming from other countries and the live-
stock products being distributed across the world.
The changes in the way livestock are raised and processed
have produced a dramatic rise in the availability of animal
source foods (Steinfeld et al., 2006). This has undoubtedly
contributed to an improved sense of well-being around the
world through the greater access to reasonably priced live-
stock protein, employment with 1.3 billion people esti-
mated to be employed in different livestock product value
chains (Herrero et al., 2009), and the sheer number of
households in developing countries involved in livestock
earning activities. It has been estimated that approximately
two-thirds of households in the developing countries earn
income from livestock (Davis et al., 2010).
Fig. 1. Global livestock units by species
(FAO, 2014 data author analysis)
1Livestock Unit = 500 kg liveweight.
2Livestock unit conversion rates: camel = 1.2; cattle and buffalo = 1;
equines = 0.7; pigs and other camelids = 0.3; sheep and goats = 0.2; turkeys
and dogs = 0.05; chickens, ducks, other poultry, cats = 0.01.
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Therefore, animals are important in societies across the
world and livestock, in particular, are critical to food sys-
tems. Animals are involved in everything we do; they com-
pete for resources such as land and water, and they pose
risks because the diseases they contract can be transferred
to humans. The role of animals in society has changed and
continues to do so. There is a tendency towards a greater
intensity with which livestock are kept, many being largely
sedentary and reliant on concentrated feeds. These changes
have given rise to different animal health problems and the
need for different systems of health management. Part of
these changes in management relate to the use of antibiotics
in livestock production, which includes the use of antibiot-
ics as either therapeutic, metaphylactic or prophylactic
measure. Increasingly, questions are being raised as to
whether the use of antibiotics is justified, and some
countries have modified their legislation in response to
problems of anti-microbial residues and emergence of anti-
microbial resistance. Thus, policies to manage animals and
the diseases they suffer from remain critical.
The following sections will provide a suggested frame-
work to examine the trade-offs in the use of antimicrobials
in livestock production. The intention is to provide some
clarity in this debate and also stimulate discussion around a
very difficult policy area of anti-microbial use.
Proposed economic frameworks to assess anti-
microbial use in animals
Anti-microbial use in livestock production is accepted and
promoted to achieve livestock production and animal wel-
fare goals at both an individual and societal level. The bene-
fits from the sale of antimicrobials accrue to the
pharmaceutical companies and the animal health profes-
sionals involved in their distribution. The livestock produc-
ers benefit from their ability to raise and harvest livestock
products with more certainty and high levels of productiv-
ity. Beyond the farm gate the slaughter and food processing
industries have benefits relating to more uniform animals
that are supplied in numbers that have low variation.
Finally, the consumers enjoy access to livestock products
that are of high quality, in quantities and price that make
them accessible.
How do we balance the benefits from antimicrobials with
the possible negative implications that could occur with
misuse and overuse of antimicrobials. Economists have
explored these trade-offs in animal health over the last
40 years. Mclnerney (1996) applied a theoretical produc-
tion economics framework to animal disease comparing
losses in production with expenditure on control. The
greater the losses the lower the expenditure with a relation-
ship between the two. Such a framework is useful in consid-
ering how a farmer would apply antimicrobials in their
production system, the antimicrobials are an expenditure
aimed at reducing losses in production. The level of appli-
cation will not necessarily lead to the complete removal of
the animal health problem, rather there is a point of equi-
librium that relates to the value of the losses avoided and
the costs of the treatment. Figure 2 indicates some of the
main points underpinning such a relationship.
In a less theoretical framework, Rushton et al. (1999)
disaggregate animal disease impacts. They identified direct
and indirect impacts – the former relating to McInerney’s
disease losses and the latter being control expenditures
Fig. 2. Disease Loss – Expenditure Frontier
(adapted from Mclnerney, 1996)
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related to human reaction to disease presence and risk. A
further modification is suggested in this study by separating
human reactions to animal health problems into three cate-
gories:
• purchasing of medicines (including antimicrobials), vac-
cines, services and diagnostics – expenditure;
• closing or restricting of markets due to the presence of
anti-microbial residues – market access;
• the use of suboptimal technologies which may be the
case if anti-microbial leads to resistance and the need to
have breeds and management systems that have a lower
overall productivity – suboptimal technology;
Human reactions to problems related to anti-microbial
use have an impact on disease losses, and there is a balanc-
ing point required where sufficient antimicrobials are used
to optimise production goals for society. Figure 3 presents
a possible framework for this structure with an overall
impact on society.
When developing a framework, one must recognise that
not all expenditure costs are equal. Some relate directly to
an animal disease management process and could be
defined as variable costs, which are defined as costs that
vary according to the level of production and are specific to
a livestock enterprise (Rushton, 2009). Anti-microbial use
at farm level would be a variable cost. Others cannot be so
easily assigned and relate to the development of infrastruc-
ture, training and organisational capacity in general, which
are defined as fixed costs that cannot easily be assigned to
an activity and are investments that are made to last for
extended period of time (Rushton, 2009). For example, the
systems required to monitor both anti-microbial residues
and anti-microbial resistance require the development of
sampling procedures, protocols for sample storage and
laboratories that can carry out tests. There is also of course
a major cost in the development and testing of new
antimicrobials, and as evidenced by the lack of recent new
antimicrobials, these costs have become very large (Davies,
2013).
These larger fixed costs are borne across society and
require a modification of the frameworks proposed by
McInerney that largely focuses on smaller, variable costs.
Tisdell (2009) proposed that countries that do not invest in
fixed cost elements of their animal health systems would
find it difficult to incorporate and succeed with individual
disease management campaigns. The development of
antimicrobials and the process to monitor anti-microbial
use, residues in animals, food and the environment and the
changes in anti-microbial resistance requires significant
societal investment that is beyond the capacity of many
countries. Tisdell (2009) developed a theoretical framework
around his arguments (see Fig. 4).
The value of these impact assessments is that they iden-
tify weaknesses in the management of antimicrobials and
the potential impacts in terms of residues or resistance
emergence. A policy change (e.g. legislation and/or direct
interventions) requires tools that examine such a change,
and the preferred tool for such assessments is a cost-benefit
analysis. This examines marginal or additional changes in
costs and benefits over time and assesses the economic
profitability of a given change.
Theories based on production economics focus on ratio-
nality and optimal solutions. A change over time requires a
time value for money in different periods which involves a
value judgement that can either be individual or societal.
The latter is often a decision made by policy makers and
can differ according to whether an investment is for a
Fig. 3. Proposed economic framework to
assess an animal health problem such as
the use of antimicrobials in animals.
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productive or consumption activity. In addition, lengthen-
ing the horizon of a changes leads to uncertainty in the out-
comes of the change, and this creates additional problems
of fitting the theory to reality. One final complication is the
institutional environment3 in which a change takes place
that can affect how differ people involved in the change can
value resources used. Overall, this added complexity
requires that backbone of theory needs to be softened, it
needs to look at the wider institutional environment in
which decisions are taken (Hennessy, 2013). A suggested
way forward would be to place anti-microbial use in an
institutional analysis and development (IAD) framework
(see Fig. 5).
The IAD framework has been successfully applied to
investigate common good management such as water, graz-
ing and security. It focuses not simply on the economic
incentives that focus on the balance between the losses
caused by the health problem and the expenditure and
other reactions of people to the presence of that problem.
It adds to the analysis to question how rules in society affect
how resources and people’s time are valued and how this
can affect decision-making within different components of
society to modify people’s behaviour. This framework cap-
tures not only the additional costs and benefits of managing
a health problem but also questions the very way society
can modify how important resources in society are valued.
An example would be the use of taxation policy for antimi-
crobials affecting the price farmers pay in their livestock
operations. The framework therefore would seem to be a
useful way to examine antimicrobials which could be con-
sidered a common good that can be affected by misuse
and/or overuse.
In a more complex example, if anti-microbial resistance
was clearly shown to pass through the food system, then a
challenge is where to intervene within that system. An
important aspect will be to assess the technical feasibility of
interventions and then to look at whether these measures
will be considered cost-effective and socially beneficial. In
complex food systems, questions need to be raised on:
• Can implementation of the intervention be verified
within the food system by people affected? that is Can
moral hazard be reduced? (Wolf, 2013)
• How will people’s decision-making be affected by the
intervention? that is What do we understand of human
behaviour?
• What do we know of the rule breakers? which requires
an understanding of the institutional setting in which
rule breaking is encouraged, not just that some people
are rule breakers.
In an example of the difficulties of looking at the biology
in the livestock food systems that are now common across
the world, there appears to be a growing recognition that
resistance emergence can have three possible routes. The
first is an underlying process of resistance that has always
been in place (D’Costa et al., 2011). Secondly, in an envi-
ronment where livestock are raised with the use of antimi-
crobials there will be evolutionary pressure for bacteria to
carry and express resistance genes; if the antimicrobials are
withdrawn from the production systems, this resistance will
reduce. A third emerging area of concern is through the
transmission across different groups of animals. This is par-
ticularly important in the types of breeding structures that
are used in poultry systems where there are pureline, grand-
parent and parent flocks and production birds. These birds
are kept in separate units, and are under different manage-
ment systems and in many cases under different ownership.
What appears to be a healthy bird entering a system has
Fig. 4. Cost-benefit model for livestock
disease control with fixed costs (adapted
fromTisdell, 2009)
3The rules that society uses that can include legislation, private standards
and cultural norms.
© 2015 The Authors. Zoonoses and Public Health Published by Blackwell Verlag GmbH  Zoonoses and Public Health 62 (suppl. 1) (2015) 10–2114
Anti-microbial Use in Animals J. Rushton
been shown to carry and transmit resistance such as
extended-spectrum beta-lactamase-producing bacteria
(Dierikx et al., 2013). Given that these populations are
shaped in a pyramid, there is evidence that changes in the
top of the pyramid can influence the bacteria with resis-
tance genes and phenotypes in the much more numerous
production birds (Laube et al., 2013). This example dem-
onstrates that actions of people in the complex food chain
can influence the resistance burdens on others animals and
also create risks to humans working with animals (Huijbers
et al., 2014) and across the food system (Egerv€arn et al.,
2014). These issues can be both dramatic in terms of scale
and have geographical implications for the spread as many
countries import birds from overseas breeding flocks.
The food system therefore needs to be pulled apart in
terms of who is involved in manufacturing, distributing,
supplying and using antimicrobials. Once in an animal the
likelihood of anti-microbial residue and resistance with a
system in place to capture these changes. These technical
outcomes need to be translated into probabilities of affect-
ing the health of animals and humans through the lower
usefulness of the antimicrobials available.
Data on the economic assessment of antimicrobials
in animals
The benefits
In pig and poultry systems, and in countries where this
practice is allowed, it is common that antimicrobials are
used as growth promoters (Dibner and Richards, 2005;
Castanon, 2007). The potential growth promoter effect of
antimicrobials was discovered in the 1940s, when it was
observed that when healthy animals were fed dried mycelia
of Streptomyces aureofaciens containing chlortetracycline
residues, their growth improved. The same approach was
advocated in the mid-1950s, as researchers found that
small, subtherapeutic quantities of antimicrobials used as
feed additives decreased the time and total feed needed to
grow an animal to market weight (Marshall and Levy,
2011).
The exact mechanism by which the antimicrobials pro-
mote greater efficiency of feed use and hence growth has
never been fully clarified (Pagel and Gautier, 2012), reflect-
ing the complexity of the impact of antimicrobials on the
microbiome and its interaction with the animal’s physio-
logical body functions. As the level of gut absorption of
some of the antimicrobials used as growth promoters is
reduced (Dibner and Richards, 2005), the actual mecha-
nism of action must be at the gut level (Dibner and Rich-
ards, 2005). These can include direct effect on the
microflora leading to decreased competition for nutrients,
reduction in microbial metabolites that depress growth and
a reduction in opportunistic pathogens and subclinical
infections (Dibner and Richards, 2005). Some of the more
recent theories point to a non-anti-microbial but anti-
inflammatory effect in the gut (Niewold, 2007), modula-
tion of gut immune responses (Costa et al., 2011) or subtle
changes in population composition of the gut microbiome
(Danzeisen et al., 2011).
Data on the faster growth generated by increasing con-
sumption of antimicrobials for growth promotion have
been published and provide a convincing argument for
use in pigs and poultry, particularly during the early
stages of life (Thomke and Elwinger, 1998) and under
poor hygiene conditions (SOU, 1997). The differences in
growth rates between animals consuming and not con-
suming AGP have been more difficult to identify in pro-
duction systems where hygiene conditions were changed
with regard to improvements in housing, feed and water.
There is increasing evidence of there being little value of
AGP in livestock production systems that have improved
hygiene standards, and the use of anti-microbial growth
promoters (AGPs) in poultry units in the US actually
reduces profit margins (Graham et al., 2007). As a note
of caution to what a appears to be a growing consensus a
recent study indicates that improvements can be found in
Fig. 5. Institutional analysis and
development framework (modified from
Ostrom, 2010)
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layer birds (Liu et al., 2014), the context of the produc-
tion system is not clear and the ability to compare stud-
ies requires more information.
The increasing awareness of the risk of resistance led to
the ban of growth promotion use in Europe. Despite such
bans, there are ways that production systems can receive
antimicrobials at low levels, and there is a need to look
more carefully at the economic incentives and the institu-
tional environment. In addition, the actual data on the
effect of the use of antimicrobials for growth promotion
were published some time ago (SOU, 1997; Thomke and
Science, 1998) and appear not to have been updated even
though feed quality, management and housing have
improved considerably. Therefore, the actual benefits of
one of the major uses of antimicrobials in livestock produc-
tion are unclear, and evidence compiled so far from Europe
(Cogliani et al., 2011) and the US (Maron et al., 2013)
indicates that anti-microbial use could be reduced with
changes in management and with minimal impacts on live-
stock production levels. Whilst some argue that Europe no
longer uses antimicrobials for growth promotion, there is
evidence that many animals are treated in batches where
only some animals are sick. The trigger for these treatments
leads to metaphylactic use. Evidence of this problem can be
seen in the need for the Dutch and Danish governments to
change their legislation and enforcement procedures to
reduce anti-microbial use in livestock production systems.
This change in the institutional environment is an impor-
tant point of reference for any successful management
programme.
In summary, the benefits of the use of antimicrobials for
curative medicine are much clearer – livestock that are sick
can be made healthy and productive again. The case on the
improved performance of healthy livestock with low levels
of anti-microbial use is less clear cut.
The costs
The possible benefits from the use of antimicrobials in ani-
mals need to be balanced against their cost and the costs of
application and the costs in humans and animals caused by
increased risk of emergence of resistance. The study will
not review the monetary costs of antimicrobials and their
application, albeit this is an important element, rather it
will focus on the externality issues that relate to the
increased risks of the emergence of resistance.
There are three potential routes that anti-microbial resis-
tance could spread from livestock production systems: (i)
through the food system, (ii) direct contact between people
and animals and (iii) through environmental contamina-
tion. These are discussed in the following sections, and
information is also provided on the potentials costs to
human health if resistance is passed to humans.
Food system transmission and direct contact
As with most public health problems, the initial reaction
to problems is to focus on the food system to ensure that
consumers are not affected. The commission who have
drawn up Codex Alimentarius have generated guidelines
on a structured risk analysis framework that addresses
the risks to human health associated with the presence in
food of bacteria carrying resistance genes or resistant
phenotypes that is linked to the use of antimicrobials in
animals or food preparation. Within the limits of the
need for compromises between members of the commis-
sion, these guidelines also provide advice on management
strategies to reduce such risks (Codex Alimentarius,
2011).
The use of fluoroquinolones (e.g. enrofloxacin) in food
animals has been linked to the development of ciprofloxa-
cin-resistant Salmonella, Campylobacter and E. coli, which
were responsible for human infections. Resistance gener-
ated to these antimicrobials through the use in animals is a
part of the resistance profile as these antimicrobials are
widely used in human medicine and the spread can be
through travel and food contamination. However, several
reports suggest that multiple E. coli human infections may
have originated in food animals, mainly poultry (Johnson
et al., 2007; Warren et al., 2008).
In terms of looking at the impacts on the human health
McEwen (2012) published a review paper, summarising the
available American quantitative human health risk assess-
ments of anti-microbial use in animals (McEwen, 2012).
Risk estimates ranged from a few additional illnesses per
million at risk, to many thousands. Comparison between
studies is however far from linear, as few of them consider
the same drug/bacterium combination or the same risk
question, and the methodologies used also differ substan-
tially (McEwen, 2012). Similar to the issue on the value of
antimicrobials for growth promotion, there is little emerg-
ing consensus.
In general, there are a number of studies that indicate an
association between anti-microbial use in livestock and
resistance in bacteria. However, few have quantified what
this subsequently means in terms of public health, which
suggest that those that fund the research do not have a
holistic picture in terms of the impact of resistance emer-
gence. Hence, there is a lack of data and information which
can lead to uninformed policy making at international and
national levels, poor development of private standards and
uninformed choice of production systems at farm level.
Snary et al. (2004) indicated that much data are available
for food system risk assessments of resistance, but it is
rarely in a format that allows strong quantitative analysis.
The Codex Alimentarius guidelines on assessing anti-
microbial resistance risks in the food system are important
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in this context as they provide an analytical structure to
guide data collection and enhance data capture.
There is a gap in the data on the relative importance
between the transmission of bacteria with resistance genes
and phenotypes to humans from animals through direct
contact versus through the food system. Understandably,
this will tend to be context specific and dependent on the
production system, the use of antimicrobials and the effec-
tiveness of the food system to manage bacterial burdens.
Yet overall the literature is poor in this critical area of man-
aging anti-microbial resistance.
Environmental contamination
There are also environmental risks associated with anti-
microbial usage: (i) the hazard of emission of antimicro-
bials into the environment, for example a significant
quantity (75–90%) of tetracycline used in food animals is
excreted largely unmetabolised into the environment and
(Chee-Sanford et al., 2001) (ii) the hazard of bacteria with
resistance genes being disseminated into the environment
when manure and urine from livestock production are
spread. The data on this dissemination are limited and
require further work to draw hard conclusions. An addi-
tional concern is the waste water from pharmaceutical
manufacturers which if left untreated has been shown to
create pockets of resistance.4
In summary, most antimicrobials given to livestock are
excreted. Their impact can be localised in terms of influ-
encing the microbiome of the animal and also more gener-
alised through the anti-microbial coming into contact with
the environment as it is excreted in the manure and urine.
Some data indicate the problems this appears to cause with
an association between the spread of manure and the exis-
tence of resistance genes in the environment (Wegener,
2012). Again, there are gaps in our knowledge of the overall
impact of the environmental externality created using
antimicrobials in livestock systems. There are also gaps in
understanding of the emergence of resistance from farm
systems are largely localised in terms of direct contact with
the animals or the environment they operate in rather than
through food borne spread. This aspect is particularly criti-
cal when we consider that little if anything has been carried
out with regard to the use of antimicrobials in companion
animals which are a smaller overall number and biomass
but are more frequently in direct contact with people.
Estimated costs of anti-microbial resistance in human
In terms of calculating the costs of anti-microbial resis-
tance, there are studies that have attempted to estimate the
monetary externalities of resistance. Kaier and Frank
(2010) measured the externality of anti-bacterial use in
human medicine and concluded that consumption of a sin-
gle defined daily dose of second-generation cephalosporins,
third-generation cephalosporins, fluoroquinolones and lin-
cosamides is associated with a negative externality of about
EUR 5, EUR 15, EUR 11 and EUR 12, respectively. This
estimate relates to increased likelihood of the emergence of
resistance, and the cost increases in health care and human
health loss associated with that increased resistance (Kaier
and Frank, 2010).
In contrast, use of one litre of alcohol-based hand rub
solution for hand disinfection is associated with a positive
externality of about EUR 61. Kaier and Moog (2012) con-
cluded that a 32% reduction in the cost of MRSA to the
German healthcare system could be reached, if the use of
fluoroquinolones and third-generation cephalosporins (in
humans) was reduced by 10%, together with the same
increase in the use of antiseptics for hand disinfection (Kaier
and Moog, 2012). Tansarli et al. (2013) looked at the in-
hospital costs attributable to anti-microbial multidrug resis-
tance on (human) inpatient care cost and concluded that
these costs are alarmingly high (Tansarli et al., 2013). For
example, with respect to MRSA, the attributable mean total
costs per patient varied from USD 1014 to 40 090, and they
varied from USD 1584 to 30 093 among studies on
extended-spectrum b-lactamase-producing Enterobacteria-
ceae. The large spread on the estimates relates to uncertain-
ties on the parameters and outcomes in individual cases.
Overall economic analysis
From an economic perspective, it is important to recog-
nise that low-level anti-microbial use in livestock influ-
ences the efficiency of feed inputs and hence the overall
productivity of a system. Yet there are trade-offs in terms
of animal health. For example, whilst antimicrobials may
enhance the growth and efficiency of livestock, it could
well lead over time to the emergence of resistance to
antimicrobials and any outbreaks of disease of organisms
with resistance genes would require the use of more
expensive antimicrobials. Conversely not using anti-micro-
bial prophylactically may increase feed costs and perhaps
costs associated with disease and death loss, but diseases
are less likely to be caused by resistant pathogens and
can often be treated with less expensive first-line anti-
microbial drugs (Mathews, 2001). The balance between
the short-term gains from using antimicrobials prophylac-
tically versus medium to long-term costs of resistance
build up illustrate in a localised sense the trade-offs that
need to be made at animal production level.
There are few studies that have attempted to look at the
trade-offs between the costs of antimicrobials and the4http://www.nature.com/news/2011/110216/full/news.2011.46.html
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benefits gained. Collignon et al. (2005) estimated that the
use of antimicrobials in livestock production does little for
malnutrition yet there analysis focussed on the use for
growth promoters rather more general use of antimicro-
bials that would include curative treatments. Graham et al.
(2007) carried out a trial in a large poultry producer in the
US where anti-microbial growth promoters were reduced.
They found that the use of antimicrobials in this way cre-
ated a cost to production, not a benefit. Vagsholm and
H€ojgard (2010) presented a careful analysis of how the
externalities need to be incorporated into a taxation mech-
anism on anti-microbial pricing. Their analysis is useful in
putting into context the need for government policies on
taxation of antimicrobials and the fact that this element of
policy making should be aiming to rectify market failure.
Smith et al. (2006) highlighted that much work is done on
resistance issues in terms of micro-level impacts and inter-
ventions to avoid or minimise the risks. They argued that
macro-level impacts needed to be examined carefully for
wider implications on the economy, as evaluations tended
to concentrate on the economic impact to the healthcare
sector alone, with poor estimation of the social costs and
benefits of a disease or intervention. Further work indicated
(Smith and Coast, 2013) that an increase in resistant organ-
isms coupled with no new anti-bacterial discovered since
1987 (Davies, 2013), and very few antivirals and anti-fun-
gals indicate a crisis. The outcome could be a need to
change how current human and animal health systems
manage infectious diseases in the future. Funding pro-
grammes are beginning to react to this challenge, and it
remains to be seen how this will evolve. What is clear is
that currently available estimates of the economic costs of
anti-microbial resistance fail to recognise that antimicro-
bials are integral to modern health care.
Overall for an area of society that is so important – ani-
mals and antimicrobials there is paucity of data and
information on changes in production, costs of use and
externalities created by changes in resistance levels. This
makes economic analysis difficult and when attempted the
answers generated are based on many assumptions.
Suggestions for the future
Impact assessment frameworks are needed to identify bot-
tlenecks in animal health and welfare management. In addi-
tion, it is important that such impact assessments collect
and document the public and private expenditure (Gilbert
and Rushton, 2014) on animal health and disease manage-
ment in order to generate information on usage of antimi-
crobials and for economic analysis to have cost profiles.
Remembering that not all antimicrobials are the same
(Acar et al., 2012) and will have varying social and eco-
nomic impacts due to their different biological actions, dif-
ferent roles in animal and human medicine and resistance
against a particularly group of antimicrobials. Many gov-
ernments currently focus their work on public expenditure
which is a partial and limited picture of expenditure across
a society, and there is a general lack of data that allow fine
detail of anti-microbial use to be specified. In order to
achieve a more complete picture the impact assessment
frameworks need to direct national and international data
collection efforts which should include species and systems
they are applied to the type of antibiotic and the dosing.
The species needs to cover companion animals as well as
food animals as it is still unknown how important they are
in the general management of resistance.
On the costs side, more attention is required on the large
fixed costs required for the development of new antimicro-
bials and in the need for pricing mechanisms that reflect
the need to cover these costs and manage resistance
(Vagsholm and H€ojgard, 2010). There must be clear infor-
mation on the capacity of the private sector to manage
fixed costs, and this is particularly relevant in situations
where livestock sectors are becoming integrated with a
small number of large companies. Economics need to be
incorporated in epidemiological models, as well as in the
monitoring and evaluation of animal health projects and
programs. The state’s role must be better defined with
regard to coordination, legislation and investment in
research and information provision. One must also under-
stand that cost-benefit analysis only provides an estimate of
economic profitability. Overall, good policy dialogue needs
to build on data from different areas of the economy, as
well as analysis that incorporates biological, technical and
economic disciplines. Figure 6 presents a summary of this
approach applied to a One health and welfare perspective.
This framework includes the use of antimicrobials and the
emergence of resistance.
Conclusion
Livestock health is important to societies across the world.
Economic analysis of animal health is complex and disease
dependent. This complexity only increases at a policy level
and requires a systems approach with interdisciplinary
working. Such analysis must account for the roles that ani-
mals play in society and the prices of resources they com-
pete for. This implies that a realistic assessment of costs
and benefits from animal health policy making will be com-
plex. The communication of results should focus on what
decisions need to be made and why, using economic princi-
ples to focus on resource allocation. Wider societal issues
such as social acceptability and political palatability should
also be considered and included. Once programmes are
established, they must be regularly reviewed with the same
rigour to avoid institutionalisation.
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Livestock are an important component of societies across
the world, yet their role is changing and the systems in
which we keep livestock have become more intensive. Part
of this change in production has been an increase use of
antimicrobials in the management of animal health and in
some cases to increase the efficiency of feed conversion in
the animals. Antimicrobials have therefore become integral
to the livestock systems that the world is increasingly
dependent on. Yet the amount and frequency of use of
antimicrobials across the world is different even in systems
with similar levels of intensification. These differences in
use are related to the rules and enforcement of anti-micro-
bial use in livestock. This institutional environment is also
evolving as anti-microbial resistance has become associated
with the use of antimicrobials in livestock production. The
emergence of resistance could be through the food systems,
which are increasingly global in their reach, and can be
through local contact and environmental contamination.
There is an awareness of these complexities in the use of
antimicrobials the emergence or resistance and the difficul-
ties of rigorous economic assessment. The study presents a
framework that could assist in approaching this through
the division of impacts into impacts caused by a health
problem across species and the costs of people’s various
reactions to such a problem. It also raises the need to
understand the institutional environment in which prices
are set for key resources and services. Applying only part of
this framework in an exploratory review of the literature on
the costs and benefits of anti-microbial use in animals indi-
cates literally the cupboard is bare. There are gaps on the
impacts of low doses of antimicrobials used as growth pro-
moters. The data on attribution of resistance emergence
from the livestock production unit and through into the
food system and the environment are limited. Plus the data
on the economic impact of resistance in human health are
variable. As stated earlier currently available estimates of
the economic costs of anti-microbial resistance fail to rec-
ognise that antimicrobials are integral to modern health
care.
Antimicrobials resistance represents a global societal
problem, a good example of a ‘Tragedy of the Commons’:
individuals are depleting a shared ‘global public good’ by
acting short term out of self-interest, even if doing so runs
contrary to the overall long-term best interest. This is gen-
erating a response from different organisations involved in
safe guarding public health, yet there are major gaps in
knowledge, data and information. These gaps create weak-
nesses in terms of decision-making on international and
national public policy and also in setting private standards
across livestock food systems. If the debate on what to do
next to find solutions to this problem is to move on there
needs to be a moratorium on what data needed to be cap-
tured, how should they be collected and where should they
be stored and analysed. If this is not performed, there will
be continuation of discussions that are based on conjecture
around the origins of resistance and how to manage this.
There is a need to move the conjecture into hypotheses fol-
lowed by scientific investigation and the sharing of results.
Acknowledgements
Contents of this article were presented in an international
expert meeting, ‘Reducing antimicrobial usage in agricul-
ture and aquaculture: beyond regulatory policy’, held in
Fig. 6. Elements required for building a
sound economic assessment of One Health
and welfare problems.
© 2015 The Authors. Zoonoses and Public Health Published by Blackwell Verlag GmbH  Zoonoses and Public Health 62 (suppl. 1) (2015) 10–21 19
J. Rushton Anti-microbial Use in Animals
Utrecht, the Netherlands, 1–3 July 2013. The Workshop
was sponsored by the OECD Co-operative Research Pro-
gramme on Biological Resource Management for Sustain-
able Agricultural Systems, the Netherlands Organization
for Health Research and Development (ZonMW) and the
Dutch Ministry of Economic Affairs. The opinions
expressed and arguments employed in this publication are
the sole responsibility of the authors and do not necessarily
reflect those of the OECD or of the governments of its
member countries.
Conflict of Interest
The authors have no conflicts of interest to declare.
References
Acar, J. F., G. Moulin, S. W. Page, and P. P. Pastoret, 2012:
Antimicrobial resistance in animal and public health: intro-
duction and classification of antimicrobial agents. Rev. Sci.
Tech. 31(1), 15–21.
Castanon, J. I. R., 2007: History of the use of antibiotic as
growth promoters in European poultry feeds. Poult. Sci. 86
(11), 2466–2471.
Chee-Sanford, J. C., R. I. Aminov, I. J. Krapac, N. Garrigues-
Jeanjean, and R. I. Mackie, 2001: Occurrence and diversity of
tetracycline resistance genes in lagoons and groundwater
underlying two swine production facilities. Appl. Environ.
Microbiol. 67(4), 1494–1502.
Codex Alimentarius, 2011: Guidelines for Risk Analysis of Food-
borne Antimicrobial Resistance (CAC/GL 77–2011). Codex
Alimentarius, Rome, Italy.
Cogliani, C., H. Goossens, and C. Greko, 2011: Restricting Anti-
microbial Use in Food Animals: Lessons from Europe. Ban-
ning nonessential antibiotic uses in food animals is intended
to reduce pools of resistance genes. Microbe 6(6), 274–279.
Collignon, P., H. C. Wegener, P. Braam, and C. D. Butler, 2005:
The routine use of antibiotics to promote animal growth does
little to benefit protein undernutrition in the developing
world. Clin. Infect. Dis. 41(7), 1007–1013.
Costa, E., R. Re Uwiera, J. P. Kastelic, L. B. Selinger, and G. D.
Inglis, 2011: Non-therapeutic administration of a model anti-
microbial growth promoter modulates intestinal immune
responses. Gut. Pathog. 3(1), 14.
Danzeisen, J. L., H. Bum Kim, R. E. Isaacson, Z. Jin Tu, and T. J.
Johnson, 2011: Modulations of the chicken cecal microbiome
and metagenome in response to anticoccidial and growth pro-
moter treatment. PLoS ONE 6(11), e27949.
Davies, S., 2013: The drugs don’t work. A global threat. Penguin,
London.
Davis, B., P. Winters, G. Carletto, K. Covarrubias, E. J.
Qui~nones, A. Zezza, K. Stamoulis, C. Azzarri, and S. DiGi-
useppe, 2010: A Cross-Country Comparison of Rural Income
Generating Activities.World Dev. 38(1), 48–63.
D’Costa, V. M., C. E. King, L. Kalan, M. Morar, W. W. L. Sung,
C. Schwarz, D. Froese, G. Zazula, F. Calmels, R. Debruyne, G.
B. Golding, H. N. Poinar, and G. D. Wright, 2011: Antibiotic
resistance is ancient. Nature 477(7365), 457–461.
Dibner, J. J., and J. D. Richards, 2005: Antibiotic growth pro-
moters in agriculture: history and mode of action. Poult. Sci.
84(4), 634–643.
Dierikx, C. M., J. A. van der Goot, H. E. Smith, A. Kant, and D.
J. Mevius, 2013: Presence of ESBL/AmpC-producing Escheri-
chia coli in the broiler production pyramid: a descriptive
study. PLoS ONE, 8(11), e79005.
Egerv€arn, M., S. B€orjesson, S. Byfors, M. Finn, C. Kaipe, S. Engl-
und, and M. Lindblad, 2014: Escherichia coli with extended-
spectrum beta-lactamases or transferable AmpC beta-lacta-
mases and Salmonella on meat imported into Sweden. Int. J.
Food Microbiol. 171, 8–14.
FAO (2014): FAOSTAT database. Available at: http://fao-
stat.fao.org.
Gerland, P., A. E. Raftery, H. Sevcikova, N. Li, D. Gu, T. Spoo-
renberg, L. Alkema, B. K. Fosdick, J. Chunn, N. Lalic, G. Bay,
T. Buettner, G. K. Heilig, and J. Wilmoth, 2014: World popu-
lation stabilization unlikely this century. Science Available at:
http://www.sciencemag.org/cgi/doi/10.1126/science.1257469
[Accessed September 19, 2014].
Gilbert, W., and J. Rushton, 2014: Estimating farm-level private
expenditure on veterinary medical inputs in England. Vet.
Rec. 174(11), 276
Graham, J. P., J. J. Boland, and E. Silbergeld, 2007: Growth pro-
moting antibiotics in food animal production: an economic
analysis. Public Health Rep. 122(1), 79–87 .
Hennessy, D. A., 2013: Biosecurity Externalities and Indemnities
for Infectious Animal Diseases. In Proceedings of the OECD
Conference on “Livestock Disease Policies: Building Bridges
between Animal Science and Economics.”Paris: OECD, pp.
139–150.
Herrero, M., P. K. Thornton, P. Gerber, and R. S. Reid, 2009:
Livestock, livelihoods and the environment: understanding
the trade-offs. Curr. Opin. Environ. Sustain. 1(2), 111–120.
Huijbers, P. M. C., E. A. M. Graat, A. P. J. Haenen, M. G. van
Santen, A. van Essen-Zandbergen, D. J. Mevius, E. van Duij-
keren, and A. H. A. M. van Hoek, 2014: Extended-spectrum
and AmpC b-lactamase-producing Escherichia coli in broilers
and people living and/or working on broiler farms: preva-
lence, risk factors and molecular characteristics. J. Antimicrob.
Chemother. 69(10), 2669–2675
Johnson, J. R., M. R. Sannes, C. Croy, B. Johnston, C. Clabots,
M. A. Kuskowski, J. Bender, K. E. Smith, P. L. Winokur, and
E. A. Belongia, 2007: Antimicrobial drug-resistant Escherichia
coli from humans and poultry products, Minnesota and Wis-
consin, 2002-2004. Emerg. Infect. Dis. 13(6), 838–846 .
Kaier, K., and U. Frank, 2010: Measuring the externality of anti-
bacterial use from promoting antimicrobial resistance. Phar-
macoeconomics 28(12), 1123–1128.
Kaier, K., and S. Moog, 2012: Economic consequences of the
demography of MRSA patients and the impact of broad-spec-
© 2015 The Authors. Zoonoses and Public Health Published by Blackwell Verlag GmbH  Zoonoses and Public Health 62 (suppl. 1) (2015) 10–2120
Anti-microbial Use in Animals J. Rushton
trum antimicrobials. Appl. Health Econ. Health Policy 10(4),
227–234.
Laube, H., A. Friese, C. von Salviati, B. Guerra, A. K€asbohrer, L.
Kreienbrock, and U. Roesler, 2013: Longitudinal monitoring
of extended-spectrum-beta-lactamase/AmpC-producing Esc-
herichia coli at German broiler chicken fattening farms. Appl.
Environ. Microbiol. 79(16), 4815–4820.
Liu, H. N., Y. Liu, L. L. Hu, Y. L. Suo, L. Zhang, F. Jin, X. A.
Feng, N. Teng, and Y. Li, 2014: Effects of dietary supplemen-
tation of quercetin on performance, egg quality, cecal microfl-
ora populations, and antioxidant status in laying hens. Poult.
Sci. 93(2), 347–353.
Maron, D. F., T. J. S. Smith, and K. E. Nachman, 2013: Restric-
tions on antimicrobial use in food animal production: an
international regulatory and economic survey. Global. Health
9, 48.
Marshall, B. M., and S. B. Levy, 2011: Food animals and antimi-
crobials: impacts on human health. Clin. Microbiol. Rev. 24
(4), 718–733.
Mathews, K. H., 2001: Antimicrobial Drug Use and Veterinary
Costs in U.S. Livestock Production. USDA Agricultural
Information Bulletin 766 May 2001 11 pages http://
www.ers.usda.gov/media/480677/aib766_1_.pdf (accessed
September 2014)
McEwen, S. A., 2012: Quantitative human health risk assess-
ments of antimicrobial use in animals and selection of resis-
tance: a review of publicly available reports. Rev. Sci. Tech. 31
(1), 261–276.
Mclnerney, J., 1996: Old economics for new problems -livestock
disease: presidential address. J. Agric. Econ. 47(1–4), 295–314.
Niewold, T. A., 2007: The nonantibiotic anti-inflammatory
effect of antimicrobial growth promoters, the real mode of
action? A hypothesis Poult. Sci. 86(4), 605–609.
Norwood, F. B., and J. L. Lusk, 2011: Compassion, by the
pound: The Economics of Farm Animal Welfare. Oxford Uni-
versity Press, New York and London.
Ostrom, E., 2010: Beyond Markets and States: Polycentric Gov-
ernance of Complex Economic Systems. Am. Econ. Rev. 100
(3), 641–672.
Pagel, S. W., and P. Gautier, 2012: Use of anti-microbial agents
in livestock. Rev. Sci. Tech. 31(1), 145–188.
Rushton, J., 2009: Economic Analysis Tools. In: Rushton, J. (ed),
The Economics of Animal Health and Production, pp. 65–
106. CABI, Wallingford, UK.
Rushton, J., P. K. Thornton, and M. J. Otte, 1999: Methods of
economic impact assessment. Rev. Sci. Tech. 18(2), 315–342.
Smith, R., and J. Coast, 2013: The true cost of antimicrobial
resistance. BMJ 346, f1493.
Smith, R. D., M. Yago, M. Millar, and J. Coast, 2006: A macro-
economic approach to evaluating policies to contain antimi-
crobial resistance: a case study of methicillin-resistant
Staphylococcus aureus (MRSA). Appl. Health Econ. Health
Policy 5(1), 55–65.
Snary, E. L., et al., 2004: Antimicrobial resistance: a microbial
risk assessment perspective. The Journal of antimicrobial che-
motherapy 53(6), 906–917.
SOU, 1997: Antimicrobial feed additives. Report from the commis-
sion on antimicrobial feed additives, Available at: http://
www.government.se/sb/d/574/a/54899.
Steinfeld, H., P. Gerber, T. Wassenaar, V. Castel, M. Rosales,
and C. De Haan, 2006: Livestock’s long shadow: Environmen-
tal issues and options. FAO, Rome, Italy. Available at: http://
www.fao.org/docrep/010/a0701e/a0701e00.HTM.
Tansarli, G. S., D. E. Karageorgopoulos, A. Kapaskelis, and M. E.
Falagas, 2013: Impact of antimicrobial multidrug resistance
on inpatient care cost: an evaluation of the evidence. Expert
Rev. Anti. Infect. Ther. 11(3), 321–331.
Thomke, S., and K. Elwinger, 1993: Growth promotants in feed-
ing pigs and poultry. I. Growth and feed efficiency responses
to antibiotic growth promotants. Annales de zootechnie, 47,
85–97.
Tisdell, C., 2009: Economics of Controlling Livestock Diseases:
Basic Theory. In: Rushton, J. (ed), Economics of Animal
Health & Production, pp. 46–49. CABI, Wallingford, UK.
Vagsholm, I., and S. H€ojgard, 2010: Antimicrobial sensitivity–A
natural resource to be protected by a Pigouvian tax? Prev. Vet.
Med. 96(1–2), 9–18.
Warren, R. E., V. M. Ensor, P. O’Neill, V. Butler, J. Taylor, K.
Nye, M. Harvey, D. M. Livermore, N. Woodford, and P. M.
Hawkey, 2008: Imported chicken meat as a potential source of
quinolone-resistant Escherichia coli producing extended-
spectrum beta-lactamases in the UK. The Journal of antimicro-
bial chemotherapy 61(3), 504–508.
Wegener, H. C., 2012: Antibiotic resistance linking human and
animal health. Improving Food Safety Through a One Health
Approach: Workshop Summary, pp. 331–349. National Acad-
emies Press, Washington DC.
Wolf, C. A., 2013: Livestock disease indemnity design: consider-
ing asymmetric information – 1. In Proceedings of the OECD
Conference on “Livestock Disease Policies: Building Bridges
between Animal Science and Economics.”Paris: OECD, pp.
127–138.
© 2015 The Authors. Zoonoses and Public Health Published by Blackwell Verlag GmbH  Zoonoses and Public Health 62 (suppl. 1) (2015) 10–21 21
J. Rushton Anti-microbial Use in Animals
